Diversity in antibody-based approaches to non-Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37785097

about

From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs.A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.Immunological evaluation of predicted linear B-cell epitopes of human CD20 antigen.

P2860

Q26852919-0E5B1E55-CA92-471E-A808-381DA68D32C5 Q33431680-AA52D44A-F5A6-45AD-AA54-03CBADB7E03F Q36216264-C013D8DC-0723-4E72-8F66-2D5FF1DCAF40 Q38166831-6A8CF959-B7C8-45A4-A58B-06B0EFDE5FBF Q38850042-53B82DC5-48D0-4FF0-AD7A-23576326C28D Q39166301-9C523956-4D90-4EA8-8E05-37BCD2B69933

P2860

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37785097

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

@en

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

@nl

type

label

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

@en

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

@nl

prefLabel

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

@en

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

@nl

P1433

Q37785097-D1363BDB-C822-422C-8E8F-DAC12AC6FD7E

P1476

Q37785097-D2459FC3-0A03-41BF-9B7C-E7F987669324

P2093

Q37785097-3D99D30D-EC98-49C6-8F19-94671FCBF42D

Q37785097-42CE9013-2283-4363-9732-DAFE8BA152D1

Q37785097-7B30F7A0-5281-4691-8FA2-7FF57B96D0EF

Q37785097-F3EED0DD-BF4A-4AFC-B4CA-A480FF436A19

P2860

Q37785097-017B2DD3-3178-463F-837B-5AEAF7E5CDF6

Q37785097-04E6EF62-2A9F-4D52-93B7-2471C40A16F7

Q37785097-0AB41DF6-5D5A-41F9-A93C-43E67753E97D

Q37785097-1C13E9D3-5E53-4B0C-8CD7-D23DBB0AFB7F

Q37785097-1CF43F87-5083-4BF4-9A0F-1B6F7F6051CD

Q37785097-2076BFF6-60D3-4E37-B3A8-1C83492E459A

Q37785097-20A1487E-5B1A-49CA-B022-11A90BD40CB9

Q37785097-228E191B-C2C4-412E-9A30-8DCB24325394

Q37785097-231ADB86-3342-4CC3-B200-7B34A67CD243

Q37785097-40D89A97-66AD-4B56-A430-753416C2715A

P304

Q37785097-F3A49A0A-A240-49F4-9875-0A3DA7F71DE1

P31

Q37785097-CE79EEA1-1819-4AF1-9144-25B05FBB732A

P356

Q37785097-A35E2ADF-CD81-41C5-B968-1A075EC073C1

P478

Q37785097-475FA4CE-6BEB-43D9-A980-E29F439A056F

P50

Q37785097-53D092AC-FE17-479E-9C21-5FE97AA4F9E3

P577

Q37785097-2A062BDF-FF11-46F2-B76D-EBB7FC7843ED

P698

Q37785097-EA6AF152-FA0B-4276-B765-717CFA152295

P921

Q37785097-828255AC-C0F7-411A-9CB5-18E532BDA503

P356

10428194.2010.500047

P1433

Leukemia & Lymphoma

P1476

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

@en

P2093

Anton Hagenbeek

http://www.w3.org/2001/XMLSchema#string

Christian Gisselbrecht

http://www.w3.org/2001/XMLSchema#string

Franck Morschhauser

http://www.w3.org/2001/XMLSchema#string

Ola Linden

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous cultures of fused cells secreting antibody of predefined specificity

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.

P304

20-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2010.500047

http://www.w3.org/2001/XMLSchema#string

P478

51 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

David G. Maloney

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20815760

http://www.w3.org/2001/XMLSchema#string

P921